Skip to main content

Advertisement

SpringerLink
Log in

The potential utility of geminin as a predictive biomarker in breast cancer

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Compared with other markers of cell proliferation, geminin is unique being expressed selectively during the proliferative phase of the cell cycle, specifically S, G2 and early mitosis, disappearing completely at the metaphase–anaphase transition. We aimed to compare the prognostic significance of geminin to that of Ki67, a proliferation marker which has been investigated in many breast cancer studies. Breast cancer tissue microarrays containing 368 tumours were stained using anti-geminin and Ki67 antibodies. Labelling index (LI) was calculated for geminin, and the percentage of positive cancer nuclei was determined for Ki67. A receiver operation characteristics analysis was used to determine the optimum cut-off value for geminin (LI ≥ 2), and for Ki67, a score of ≥14 % was considered as positive for survival analysis. Geminin expression correlated positively with Ki67 expression (r = 0.686, p = 0.001). Survival analysis showed only geminin, and not Ki67-positive patients to have poor (breast cancer-specific survival) BCSS [HR 2.85 (1.53–5.32)] and (disease-free survival) DFS [HR 2.63 (1.47–4.71)]. On univariate analysis, along with known clinicopathological variables, both Ki67 and geminin LI were found to be significant predictors of BCSS and DFS. On multivariate analysis, only tumour size, nodal status and adjuvant hormonal therapy were found to be independent predictors for both BCSS and DFS, while geminin positivity (LI ≥ 2 %) was found to be an independent predictor for BCSS [HR 2.27 (1.01–5.06); p = 0.04]. In comparison with Ki67, a more established proliferation marker, geminin expression was a better predictor of adverse outcome in this cohort of breast cancers. Selective expression of geminin during the proliferative phase of the cell cycle and its nuclear specificity increase its potential to be used as an alternative marker of proliferation in breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    Article  CAS  PubMed  Google Scholar 

  2. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP (1990) Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer 65(5):1180–1184

    Article  CAS  PubMed  Google Scholar 

  3. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103(22):1656–1664

    Article  CAS  PubMed  Google Scholar 

  4. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 26(7):1059–1065

    Article  CAS  PubMed  Google Scholar 

  5. Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J (2011) Predictive algorithms for adjuvant therapy: TransATAC. Steroids 76(8):777–780

    Article  CAS  PubMed  Google Scholar 

  6. Faratian D, Munro A, Twelves C, Bartlett JMS (2009) Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 54(2):254–257

    Article  PubMed  Google Scholar 

  7. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174–183

    Article  CAS  PubMed  Google Scholar 

  8. McGarry TJ, Kirschner MW (1998) Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 93(6):1043–1053

    Article  CAS  PubMed  Google Scholar 

  9. Wohlschlegel JA, Kutok JL, Weng AP, Dutta A (2002) Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol 161(1):267–273

    Article  CAS  PubMed  Google Scholar 

  10. Eward KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, Jung HI, Prevost AT, Blow JJ, Stoeber K et al (2004) DNA replication licensing in somatic and germ cells. J Cell Sci 117(Pt 24):5875–5886

    Article  CAS  PubMed  Google Scholar 

  11. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH (2005) Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11(7):2510–2517

    Article  CAS  PubMed  Google Scholar 

  12. Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, Pinder SE, Laskey RA, Coleman N (2004) Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 204(2):121–130

    Article  CAS  PubMed  Google Scholar 

  13. Blanchard Z, Malik R, Mullins N, Maric C, Luk H, Horio D, Hernandez B, Killeen J, Elshamy WM (2011) Geminin overexpression induces mammary tumors via suppressing cytokinesis. Oncotarget 2(12):1011–1027

    PubMed  Google Scholar 

  14. Gardner L, Malik R, Shimizu Y, Mullins N, ElShamy WM (2011) Geminin overexpression prevents the completion of topoisomerase IIalpha chromosome decatenation, leading to aneuploidy in human mammary epithelial cells. Breast Cancer Res 13(3):R53

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Diagnostics ftSSotN-EWGoC: reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184

    Article  CAS  PubMed  Google Scholar 

  16. Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL et al (2012) A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 133(3):949–958

    Article  CAS  PubMed  Google Scholar 

  17. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750

    Article  CAS  PubMed  Google Scholar 

  18. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Shulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R et al (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163(1):217–229

    Article  CAS  PubMed  Google Scholar 

  19. Nishihara K, Shomori K, Tamura T, Fujioka S, Ogawa T, Ito H (2009) Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance. Oncol Rep 21(5):1189–1195

    CAS  PubMed  Google Scholar 

  20. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212–7220

    Article  CAS  PubMed  Google Scholar 

  21. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17(4):323–334

    Article  CAS  PubMed  Google Scholar 

  22. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26(34):5569–5575

    Article  PubMed  Google Scholar 

  23. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, Gui G, Sacks N, Ebbs SR, Allum W et al (2003) Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89(6):1035–1041

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M (2000) Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89(11):2145–2152

    Article  CAS  PubMed  Google Scholar 

  25. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99(2):167–170

    Article  CAS  PubMed  Google Scholar 

  26. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10):1504–1513

    Article  PubMed Central  PubMed  Google Scholar 

  27. Jonat W, Arnold N (2011) Is the Ki-67 labelling index ready for clinical use? Ann Oncol 22(3):500–502

    Article  CAS  PubMed  Google Scholar 

  28. Haruki T, Shomori K, Hamamoto Y, Taniguchi Y, Nakamura H, Ito H (2011) Geminin expression in small lung adenocarcinomas: implication of prognostic significance. Lung Cancer 71(3):356–362

    Article  PubMed  Google Scholar 

  29. Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, Hidaka T, Sugiyama K, Kurisu K (2007) Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer 109(5):949–956

    Article  CAS  PubMed  Google Scholar 

  30. Dudderidge TJ, McCracken SR, Loddo M, Fanshawe TR, Kelly JD, Neal DE, Leung HY, Williams GH, Stoeber K (2007) Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 96(9):1384–1393

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM (2008) Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med 37(5):309–318

    Article  CAS  PubMed  Google Scholar 

  32. Di Bonito M, Cantile M, Collina F, Scognamiglio G, Cerrone M, La Mantia E, Barbato A, Liguori G, Botti G (2012) Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer. J Breast Cancer 15(2):162–171

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful to the Leeds Teaching Hospitals NHS Trust Special Trustees for funding this work. HHT is funded by the Cancer Research UK.

Conflict of interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Leeds Institute of Cancer Studies and Pathology, University of Leeds, Leeds, LS9 7TF, UK

    Sreekumar Sundara Rajan, Andrew M. Hanby, Helene H. Thygesen & Valerie Speirs

  2. Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK

    Sreekumar Sundara Rajan, Andrew M. Hanby & Kieran Horgan

Authors
  1. Sreekumar Sundara Rajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Hanby
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kieran Horgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helene H. Thygesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valerie Speirs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valerie Speirs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sundara Rajan, S., Hanby, A.M., Horgan, K. et al. The potential utility of geminin as a predictive biomarker in breast cancer. Breast Cancer Res Treat 143, 91–98 (2014). https://doi.org/10.1007/s10549-013-2786-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2786-5

Keywords

Search

Navigation